The Microfluidics market is projected to reach USD 32.67 Billion by 2029 from USD 22.43 in 2024, growing at a CAGR of 7.8% during the forecast period. The requirement for microfluidic platforms has risen due to the growing focus on genomics and proteomics. These platforms helps in fluid regulation in biological investigations and high-throughput analysis. Moreover, microfluidic technology are widely preferred due to its integration with artificial intelligence.
Microfluidics-based devices accounted for the largest share of the Microfluidics market.
Based on the product segment, the Microfluidics market is segmented into – Microfluidics-based devices and microfluidic components. Advanced instruments that can regulate and analyze small volumes of fluids are microfluidics-based devices. They accurately manipulate fluid flow by etching micro-scale channels and chambers into substrates. These devices are also utilized in organ-on-a-chip (OOC) platforms that mimic human organ functions to help in drug testing and disease-related research, and lab-on-a-chip (LoC) systems that combine several laboratory processes in a single chip. Revogene, a microfluidics cartridge-based real-time PCR system that can conduct tests for C. difficile, Stret B., and Streptococcus A while offering results in approximately two minutes, is an example of a microfluidics-based POCT device. These devices also include assays and microfluidic sensors that offer precise detection of pathogens, biomolecules and other chemical compounds.
In Vitro Diagnostics accounts for the largest share in 2023
In vitro diagnostics (IVD) can accurately regulate and analyze minute fluid volume due to its integration with microfluidic technology. This inclusion increases the speed of test as well as makes it cheaper, accurate and more automated in IVD systems. This technique can be useful for diagnostic purposes, from blood and urine tests to complex assays for infectious diseases. An advanced technique developed in 2023 by IBM Research and Technion-Israel Institute of Technology has improved the accuracy of protein detection in immunoassays by more than 1,000 times when compared to conventional immunoassay techniques by using a microfluidic chip with channels for circulation as thin as human hair. Furthermore, the growing demand for point-of-care testing is enhancing the use of microfluidics in IVD.
By end user hospitals and diagnostic centers for the largest share in 2023
Hospitals and diagnostic centers holds the largest share in microfluidics market by end user because of their important role in providing precise and faster medical testing and diagnostics. These organizations require microfluidic technology as they need advanced solutions to precisely and efficiently handle numerous tests. Significant advantages of microfluidics comprise decreased sample and reagent use and enhanced diagnostic precision. Furthermore, the rise in demand of point-of-care testing helps in rapid diagnostic outcomes.
North America dominates the Microfluidics market in 2023.
The microfluidics market is dominated by North America for numerous reasons. The region has a well-developed healthcare system and a wide network of hospitals, clinics, and research laboratories that adopt novel technologies. The adoption and application of microfluidics into diagnostic applications is made easier due to such facilities. Furthermore, the presence of prominent players in North America drives growth as they consistently focuses on technological innovation and market expansion. Furthermore, the microfluidics market is growing in North America due to expenditure in R&D as well funding and support offered by the government. For instance, with the aid of Centre for Research and Applications in Fluidic Technologies (CRAFT), a collaboration was made between the University of Toronto, the National Research Council of Canada, and Unity Health Toronto through which Canada has achieved significant strides in the microfluidics sector. This campaign secured USD 21 million investment on February 28, 2024, to initiate research in organ-on-chip technology, biofabrication, and diagnostics.
